We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-15.4%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$9.91B
AUM Growth
-$2.06B
Cap. Flow
+$62M
Cap. Flow %
0.63%
Top 10 Hldgs %
40.04%
Holding
153
New
17
Increased
26
Reduced
29
Closed
21

Top Buys

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$123M
2
WMGI
Wright Medical Group Inc
WMGI
+$120M
3
LLY icon
Eli Lilly
LLY
+$107M
4
HCA icon
HCA Healthcare
HCA
+$72.7M
5
DVAX
Dynavax Technologies
DVAX
+$70M

Top Sells

Rank Stock Value
1
MDVN
MEDIVATION, INC.
MDVN
+$161M
2
SHPG
Shire pic
SHPG
+$153M
3
TRNX
TORNIER N V SHARES (NLD)
TRNX
+$120M
4
RCPT
RECEPTOS INC COM STK (DE)
RCPT
+$119M
5
GILD icon
Gilead Sciences
GILD
+$79M

Sector Composition

Rank Sector Weight
1 Healthcare 92.06%
2 Financials 0.24%
3 Technology 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMY icon
1
Bristol-Myers Squibb
BMY
$130B
$513M 5.18%
8,668,100
+917,000
+12% +$58.2M
HCA icon
2
HCA Healthcare
HCA
$92.8B
$452M 4.56%
5,837,900
+820,500
+16% +$72.7M
AMGN icon
3
Amgen
AMGN
$212B
$417M 4.21%
3,013,000
+132,000
+5% +$20.8M
BSX icon
4
Boston Scientific
BSX
$68.5B
$394M 3.98%
24,007,200
+2,327,200
+11% +$39.8M
AGN
5
DELISTED
Allergan plc
AGN
$392M 3.96%
1,443,315
-68,000
-4% -$20.9M
CELG
6
DELISTED
Celgene Corp
CELG
$389M 3.92%
3,593,000
-233,000
-6% -$28.9M
BIIB icon
7
Biogen
BIIB
$30.4B
$382M 3.85%
1,307,400
+28,500
+2% +$9.41M
ABBV icon
8
AbbVie
ABBV
$465B
$378M 3.81%
6,943,200
+278,200
+4% +$18.1M
ALXN
9
DELISTED
Alexion Pharmaceuticals
ALXN
$348M 3.52%
2,226,600
+182,200
+9% +$33.2M
INCY icon
10
Incyte
INCY
$26B
$302M 3.05%
2,740,978
+426,478
+18% +$47.8M
IPXL
11
DELISTED
Impax Laboratories, Inc.
IPXL
$235M 2.37%
6,664,100
-75,100
-1% -$3.38M
REGN icon
12
Regeneron Pharmaceuticals
REGN
$72.9B
$227M 2.29%
487,700
+25,900
+6% +$13.9M
MOH icon
13
Molina Healthcare
MOH
$10.5B
$223M 2.25%
3,236,300
-251,600
-7% -$18.7M
GILD icon
14
Gilead Sciences
GILD
$167B
$214M 2.17%
2,184,400
-711,000
-25% -$79M
HNT
15
DELISTED
HEALTH NET INC
HNT
$205M 2.07%
3,397,800
-304,400
-8% -$20.2M
ILMN icon
16
Illumina
ILMN
$29.2B
$202M 2.04%
1,183,228
– –
COO icon
17
Cooper Companies
COO
$14.1B
$194M 1.96%
5,205,600
– –
ICPT
18
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$186M 1.88%
1,120,000
– –
TMO icon
19
Thermo Fisher Scientific
TMO
$214B
$167M 1.68%
1,364,000
-38,000
-3% -$4.95M
WMGI
20
DELISTED
Wright Medical Group Inc
WMGI
$166M 1.68%
8,142,000
+4,805,000
+144% +$120M
NBIX icon
21
Neurocrine Biosciences
NBIX
$18.4B
$152M 1.53%
3,816,050
-1,278,450
-25% -$61.8M
RLYP
22
DELISTED
RELYPSA INC COM
RLYP
$137M 1.38%
7,400,000
– –
SHPG
23
DELISTED
Shire pic
SHPG
$136M 1.38%
664,400
-641,600
-49% -$153M
MCK icon
24
McKesson
MCK
$104B
$130M 1.31%
700,000
-18,000
-3% -$3.82M
TEVA icon
25
Teva Pharmaceuticals
TEVA
$36.9B
$124M 1.25%
2,199,000
+1,892,000
+616% +$123M
1
2 3 4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q3 2015 Portfolio in Review

As of Q3 2015, OrbiMed held 153 positions worth $9.91B, down 17% from $12B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

OrbiMed's Q3 2015 filing shows 17 new, 26 increased, 29 reduced and 21 closed positions. Its largest new stake was Eli Lilly: 1,272,000 shares worth $106M. The largest sale was MEDIVATION, INC., an estimated $161M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 87% a quarter earlier, followed by Financials and Technology.

  • OrbiMed's largest Q3 2015 buy was Eli Lilly: 1,272,000 shares worth $106M.
  • OrbiMed added most to Teva Pharmaceuticals in Q3 2015, an estimated $123M increase.
  • OrbiMed's biggest Q3 2015 reduction was Shire pic, cutting an estimated $153M.
  • OrbiMed fully exited MEDIVATION, INC. in Q3 2015, selling an estimated $161M.
  • OrbiMed's ten largest holdings make up 40% of its $9.91B portfolio in Q3 2015.
  • OrbiMed opened 17 new positions and closed 21 in Q3 2015.
  • OrbiMed's portfolio value fell 17% quarter-over-quarter to $9.91B.

Based on OrbiMed's 13F filing for Q3 2015, filed 13 Nov 2015.